arrow
J

Joan Maurel

instituto de salud carlos iii
H指数:46
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time

利用真实世界数据研究在晚期癌症护理中何时将生物疗法添加到细胞毒性疗法中:如何避免产生不归者时间的设计选择

2026-06-190
OAAI
Prognostic value of whole lymph node molecular analysis in colorectal cancer: a prospective multicenter study

结直肠癌中全淋巴结分子分析预后价值:一项前瞻性多中心研究

2025-11-250
OAAI
Effect of the composite quality resection score for rectal cancer on oncological outcomes in a multicentre cohort study (CRONOS)

复合质量切除评分对结直肠癌患者肿瘤学结局的影响(多中心队列研究CRONOS)

2025-10-280
PRE
Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial
2024-06-010
PRE
First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
2023-10-010
PRE
The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
2023-10-010
PRE
Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study

在CRONOS研究中,新辅助治疗结束与局部晚期直肠癌选择性切除术之间的时间间隔

2023-09-0114
OA
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
2023-07-056
PRE
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
CANCER
IF5.1
2023-04-251
OAAI
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

用于II期和III期结直肠癌的风险分层和对基于FOLFOX的辅助治疗的反应预测的microRNA签名

2023-01-204
OAAI